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In vivo Performance 
Atorvastatin calcium is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co A) reductase. This enzyme catalyses the conversion of HMGCo A to mevalonate, an early and rate limiting step in cholesterol biosynthesis [1] [2] . Nicotinic acid (NIC) is chemically pyridine-3-caroboxylic acid. Nicotinic acid lowers plasma triglyceride and cholesterol concentration. It acts as an antilipolytic drug in adipose tissue, increases the activity of lipoprotein lipase and decreases esterification of triglycerides in liver. It is used for Pellagra and in hyperlipoproteinaemia.
A literature survey regarding quantitative analysis of these drugs revealed that attempts were made to develop analytical methods for ATV using extractive spectrophotometry 3 , HPLC [4] [5] [6] [7] [8] , GC-MS 9 , LC-MS 10 , LC-electrospray tandem mass spectrometry [11] [12] [13] and HPTLC 14 methods, while for estimation of ATV and aspirin combination HPLC 15 method had been reported. Estimation of NIC had been reported by methods like HPLC [16] [17] [18] [19] , capillary electrophoresis 20 and light-induced photo transformation 21 of nicotinic acid with laser and UV.
ATV and NIC combination is available in the market in the form of a tablet. This paper describes reverse phase high performance liquid chromatographic method for the estimation of ATV and NIC combination in mixture in tablet dosage form.
A High performance liquid chromatographic instrument (Shimadzu HPLC class VP series) with LC-10AT VP pump, variable wavelength programmable UV/Vis detector SPD-10AVP and Rheodyne injector (7725i) with 20 µl Þ xed loop was used. Chromatographic analysis was performed using Spinchrom Software on a Phenomenex Luna C-18 column with 250×4.6 mm i.d. and 5 µm particle size. Chromatographic estimation was performed on an equilibrated C18 column using mobile phase 0.02 M potassiumdihydrogen phosphate:methanol:acetonitrile (20:40:40, pH 4) and detection was performed at 240 nm. The sample was injected using a 20 µL fixed loop, and the total run time was 10 min. Analytically pure ATV and NIC were obtained as gift samples from M/s Blue Cross Labs. Ltd., (Mumbai, India) and M/s Torrent Pharmaceutical Ltd., (Ahmedabad, India). Acetonitrile, methanol, water (E. Merck, Mumbai, India) were of HPLC grade, while ortho-phosphoric acid and potassium dihydrogen phosphate (S. D. dilutions and the quantities of drugs were determined. Limit of detection (LOD) was the concentration that yielded signal to noise ratio (S/N) 3:1 and limit of quantification (LOQ) was the concentration that yielded signal to noise ratio (S/N) 10:1. Robustness of the method was studied by changing the composition of organic phase by ±5% and the pH by ±0.2, and also by observing the stability of the drugs for 24 h at 35±2 o temperature in the mobile phase.
Selection of mobile phase was performed based on resolution, asymmetric factors and theoretical plates obtained for both ATV and NIC. The mobile phase 0.02 M potassium dihydrogen phosphate: methanol:acetonitrile (20:40:40, pH 4) was found to be satisfactory and gave two well-resolved peaks for ATV and NIC. The retention time for ATV and NIC mg of NIC were procured from a local pharmacy store.
A 1000 µg/ml stock solution of ATV and NIC in methanol was prepared separately. ATV solution was further diluted with methanol to obtain final concentration of 100 µg/ml. Appropriate aliquots of ATV and NIC stock solutions were diluted in mobile phase to obtain Þ nal concentrations of 2, 4, 8, 12, 20, 24 µg/ ml of ATV and 60, 80, 100, 150, 200, 250 µg/ ml of NIC. The solutions were injected using a 20 µL Þ xed loop system and chromatograms were recorded. Calibration curves were constructed by plotting average peak area versus concentrations and regression equations were computed for ATV and NIC.
Twenty tablets were weighed and finely powdered. Powder equivalent to ATV 10.34 mg and 375 mg NIC was accurately weighed and transferred to a 50 ml volumetric ß ask and 20 ml of mobile phase was added to the same. The ß ask was shaken, and the volume was diluted to the mark with the same mixture. The above solution was Þ ltered and appropriate volume of the aliquot was transferred to a 50 ml volumetric flask. The volume was made up to the mark with mobile phase to obtain 4.13 µg/ml of ATV and 150 µg/ml of NIC. The solution was injected at above chromatographic conditions and peak areas were measured. The quantification was carried out by keeping these values to the straight line equation of calibration curve.
The method was validated for accuracy, precision, specificity, detection limit, quantification limit and robustness. The accuracy of the method was determined by calculating recoveries of ATV and NIC by method of standard additions. The intra day and inter day precision study of ATV and NIC was carried out by estimating the corresponding responses 3 times on the same day and on 3 different days for 3 different concentrations of ATV (4, 8, 12 µg/ml) and NIC (100, 150, 200 µg/ml). The repeatability studies were carried out by estimating response of three different concentrations of ATV (2, 4, 8 µg/ml) and NIC (80, 100, 200 µg/ml) for triplicate and results are reported in terms of relative standard deviation (RSD). For specificity study commonly used excipients (starch, microcrystalline cellulose and magnesium stearate) present in selected tablet formulation were spiked into a pre weighed quantity of drugs. The chromatogram was taken by appropriate were 3.6 min and 2.4 min, respectively (Þ g. 1). The resolution was found to be 6.9, which indicates good separation of peaks for both the compounds. The asymmetric factors for ATV and NIC were 1.4 and 1.57, respectively. UV overlain spectra of both the ATV and NIC showed that both the drugs absorbs appreciably at 240 nm so, 240 nm was selected as the detection wavelength in liquid chromatography.
The calibration curve for ATV was obtained by plotting the peak area of ATV versus concentration of ATV over the range of 2-24 µg/ml, and it was found to be linear with r = 0.9998. Similarly, the calibration curve for NIC was obtained over the range of 60-250 µg/ml and was found to be linear with r= 0.9993. The data of regression analysis of the calibration curves are shown in Table 1 . The recoveries of ATV and NIC were found to be in the range of 97.93 -101.16% and 98.82-101.30%, respectively. The validation parameters are summarized in Table 2 . The proposed liquid chromatographic method was applied to the determination of ATV and NIC in their combined dosage forms (Tablet A and B). The results for ATV and NIC were comparable with the corresponding labeled amounts (Table 3) .
Thus in proposed study, RP-HPLC method has been developed for determination of ATV and NIC in combined dosage form. The method was validated and found to be simple, sensitive, accurate and precise. The method was successfully applied for determination of drugs in their pharmaceutical formulations hence method can be used for routine analysis of ATV and NIC in combined dosage form.
